Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 57, 37, 4, 81, 28 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.
Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 57, 37, 4, 81, 28 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.
Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Introduction
Atopic Dermatitis (Atopic Eczema) - Overview
Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Drug Profiles
Atopic Dermatitis (Atopic Eczema) - Dormant Projects
Atopic Dermatitis (Atopic Eczema) - Discontinued Products
Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Adare Pharma Solutions, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akeso Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Alexion Pharmaceuticals Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergy Therapeutics Plc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amicogen Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amytrx Therapeutics Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Annji Pharmaceutical Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Biotherapeutics Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Attillaps Holdings Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Avixgen Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Beijing Puqi Pharmaceutical Technology Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by BenevolentAI Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by BiomX Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Biosion Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Nepsone ehf, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Neuracle Science Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Next Science Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by NovaCell Technology Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Novan Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by NovaRock Biotherapeutics Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Novartis AG, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Numab Therapeutics AG, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Oasis Pharmaceuticals LLC, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by OliX Pharmaceuticals Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Ondek Pty Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Oneness Biotech Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Orgenesis Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Otsuka Holdings Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Panolos Bioscience, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Pantherics Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by PeLeMed Co Ltd, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Pfizer Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Pipeline by Provectus Biopharmaceuticals Inc, 2021
Atopic Dermatitis (Atopic Eczema) - Dormant Projects, 2021
Atopic Dermatitis (Atopic Eczema) - Discontinued Products, 2021
List Of Figures
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
RELATED REPORTS
Atopic Keratoconjunctivitis (Ophthalmology) - Drugs in Development, 2021
Atopic Keratoconjunctivitis (Ophthalmology) - Drugs in Development, 2021Atopic Keratoconjunctivitis (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Atopic Keratoconjunctivitis pipeline landscape.The report provides comprehensive information on the
View ReportCOVID-19 Outbreak-Global Canine Atopic Dermatitis Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
The Canine Atopic Dermatitis Treatment market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak
View ReportGlobal Canine Atopic Dermatitis Market Outlook
Global Canine Atopic Dermatitis Market is anticipated to rise at a value CAGR of 9.1% over 2019-2028. Global Canine Atopic Dermatitis Market, Canine atopic dermatitis is a commonly found skin
View ReportCOVID-19 Outbreak-Global Canine Atopic Dermatitis Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
The Canine Atopic Dermatitis Treatment market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
